BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 9392336)

  • 41. Correlation of endothelial nitric oxide synthase and vascular endothelial growth factor expression with malignancy in patients with astrocytic tumors.
    Erdamar S; Bagci P; Oz B; Dirican A
    J BUON; 2006; 11(2):213-6. PubMed ID: 17318973
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased microglia proliferation separates pilocytic astrocytomas from diffuse astrocytomas: a double labeling study.
    Klein R; Roggendorf W
    Acta Neuropathol; 2001 Mar; 101(3):245-8. PubMed ID: 11307624
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CDC25B, Ki-67, and p53 expressions in reactive gliosis and astrocytomas.
    Suren D; Isiksacan Ozen O
    J BUON; 2013; 18(4):1006-11. PubMed ID: 24344030
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of immunohistochemistry in predicting behavior of astrocytic tumors.
    Ambroise MM; Khosla C; Ghosh M; Mallikarjuna VS; Annapurneswari S
    Asian Pac J Cancer Prev; 2010; 11(4):1079-84. PubMed ID: 21133628
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Progesterone receptor isoforms expression pattern in human astrocytomas.
    González-Agüero G; Ondarza R; Gamboa-Domínguez A; Cerbón MA; Camacho-Arroyo I
    Brain Res Bull; 2001 Sep; 56(1):43-8. PubMed ID: 11604247
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic Value of ALDH1, EZH2 and Ki-67 in Astrocytic Gliomas.
    Ahmed S; Rashed H; Hegazy A; Mohamed AM; Elmesallamy W
    Turk Patoloji Derg; 2016; 32(2):70-81. PubMed ID: 27136105
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of gemistocytes in astrocytoma progression.
    Watanabe K; Tachibana O; Yonekawa Y; Kleihues P; Ohgaki H
    Lab Invest; 1997 Feb; 76(2):277-84. PubMed ID: 9042164
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cyclin D1 and MIB-1 immunohistochemistry in pilocytic astrocytomas: a study of 48 cases.
    Machen SK; Prayson RA
    Hum Pathol; 1998 Dec; 29(12):1511-6. PubMed ID: 9865840
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma.
    Abdulrauf SI; Edvardsen K; Ho KL; Yang XY; Rock JP; Rosenblum ML
    J Neurosurg; 1998 Mar; 88(3):513-20. PubMed ID: 9488306
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic significance of Hsp-27 in astrocytic brain tumors: an immunohistochemical study.
    Assimakopoulou M; Sotiropoulou-Bonikou G; Maraziotis T; Varakis I
    Anticancer Res; 1997; 17(4A):2677-82. PubMed ID: 9252700
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expression of the angiogenic factor thymidine phosphorylase in human astrocytic tumors.
    Takano S; Tsuboi K; Matsumura A; Tomono Y; Mitsui Y; Nose T
    J Cancer Res Clin Oncol; 2000 Mar; 126(3):145-52. PubMed ID: 10741908
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Insights into the prognostic value of DJ-1 and MIB-1 in astrocytic tumors.
    Abd El Atti RM; Abou Gabal HH; Osman WM; Saad AS
    Diagn Pathol; 2013 Jul; 8():126. PubMed ID: 23902708
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Telomerase activity and alterations in telomere length in human brain tumors.
    Hiraga S; Ohnishi T; Izumoto S; Miyahara E; Kanemura Y; Matsumura H; Arita N
    Cancer Res; 1998 May; 58(10):2117-25. PubMed ID: 9605755
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The expression of the epitope H recognized by the monoclonal antibody H is higher in astrocytomas compared to anaplastic astrocytomas and glioblastomas.
    Arvanitis DL; Arvanitis LD; Panourias IG; Kitsoulis P; Kanavaros P
    Histol Histopathol; 2005 Oct; 20(4):1057-63. PubMed ID: 16136487
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tenascin expression in astrocytomas correlates with angiogenesis.
    Zagzag D; Friedlander DR; Miller DC; Dosik J; Cangiarella J; Kostianovsky M; Cohen H; Grumet M; Greco MA
    Cancer Res; 1995 Feb; 55(4):907-14. PubMed ID: 7531617
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cell proliferation patterns in the diagnosis of astrocytomas, anaplastic astrocytomas and glioblastoma multiforme: a Ki-67 study.
    Raghavan R; Steart PV; Weller RO
    Neuropathol Appl Neurobiol; 1990 Apr; 16(2):123-33. PubMed ID: 2161084
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas.
    Johannessen AL; Torp SH
    Pathol Oncol Res; 2006; 12(3):143-7. PubMed ID: 16998593
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices.
    Ono Y; Tamiya T; Ichikawa T; Kunishio K; Matsumoto K; Furuta T; Ohmoto T; Ueki K; Louis DN
    J Neuropathol Exp Neurol; 1996 Oct; 55(10):1026-31. PubMed ID: 8857999
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interobserver reproducibility of MIB-1 labeling index in astrocytic tumors using different counting methods.
    Hsu CY; Ho DM; Yang CF; Chiang H
    Mod Pathol; 2003 Sep; 16(9):951-7. PubMed ID: 13679460
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of molecular markers in low-grade diffuse astrocytomas: loss of p16 and retinoblastoma protein expression is associated with short survival.
    Hilton DA; Penney M; Evans B; Sanders H; Love S
    Am J Surg Pathol; 2002 Apr; 26(4):472-8. PubMed ID: 11914625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.